Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Music
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/61/e8/34/61e834e8-b699-9622-aad5-8bdb1249e844/mza_7668263994496175852.jpg/600x600bb.jpg
Heart Failure in Focus
Radcliffe Cardiology
9 episodes
9 months ago
In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they? In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice. Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO. This podcast is supported by an unrestricted educational grant from AstraZeneca.
Show more...
Science
RSS
All content for Heart Failure in Focus is the property of Radcliffe Cardiology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they? In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice. Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO. This podcast is supported by an unrestricted educational grant from AstraZeneca.
Show more...
Science
https://i1.sndcdn.com/artworks-K5hmoiSPki4g3NxB-56X5uw-t3000x3000.jpg
Heart Failure in Focus Podcast - Teaser
Heart Failure in Focus
1 minute 11 seconds
3 years ago
Heart Failure in Focus Podcast - Teaser
Presenting our new podcast series Heart Failure in Focus, hosted by Muthiah Vaduganathan.
Heart Failure in Focus
In the last year we have seen the publication of multiple guidance documents on the management of heart failure, each setting new standards for the management of HFpEF, including two national guidelines and a consensus statement on the phenotyping of HFpEF. Why do we need so many guidance documents? What was the rationale behind their development? And how concordant are they? In the final episode of Heart Failure in Focus for 2023, Dr Muthiah Vaduganathan is joined by Prof Giuseppe Rosano (St George’s Hospital London, UK), who played a central part in the development of the 2023 European heart failure guideline focussed update and an earlier publication on HFpEF phenotyping. He shares his thoughts on these aforementioned questions and together with our host, provide a practical interpretation of how to incorporate the three distinct documents into daily practice. Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO. This podcast is supported by an unrestricted educational grant from AstraZeneca.